date,text,url,form,accepted_time
2020-07-27," 8-k 1 tm2025509d1_8k.htm form 8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): july 21, 2020 deerfield healthcare technology acquisitions corp. (exact name of registrant as specified in its charter) delaware 001-39391 85-0992224 (state or other jurisdiction of incorporation) (commission file number) (irs employer identification no.) 780 third avenue, 37th floor new york, new york 10017 (address of principal executive offices, including zip code) registrant’s telephone number, including area code: (212) 551-1600 not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ¨soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ¨pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ¨pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (§230.405 of this chapter) or rule 12b-2 of the securities exchange act of 1934 (§240.12b-2 of this chapter). emerging growth company x if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one share of class a common stock and one-fifth of one redeemable warrant dfhtu the nasdaq stock market llc class a common stock, par value $0.0001 per share dfht the nasdaq stock market llc warrants, each whole warrant exercisable for one share of class a common stock, each at an exercise price of $11.50 per share dfhtw the nasdaq stock market llc item 8.01.other events. on july 21, 2020, deerfield healthcare technology acquisitions corp. (the “company”) consummated its initial public offering (“ipo”) of 14,375,000 units (the “units”), including the issuance of 1,875,000 units as a result of the underwriters’ exercise of their over-allotment option in full. each unit consists of one share of class a common stock of the company, par value $0.0001 per share (the “class a common stock”), and one-fifth of one redeemable warrant of the company (each, a “warrant”), each whole warrant entitling the holder thereof to purchase one share of class a common stock for $11.50 per share, subject to adjustment. the units were sold at a price of $10.00 per unit, generating gross proceeds to the company of $143,750,000. on july 21, 2020, simultaneously with the consummation of the ipo, the company completed the private sale (the “private placement”) of an aggregate of 2,916,667 warrants (the “private placement warrants”) to dfhta sponsor llc at a purchase price of $1.50 per private placement warrant, generating gross proceeds to the company of $4,375,000. a total of $143,750,000, comprised of $141,211,000 of the proceeds from the ipo (which amount includes $4,443,250 of the underwriters’ deferred discount) and $2,539,000 of the proceeds of the sale of the private placement warrants, was placed in a u.s.- based trust account at j.p. morgan chase bank, n.a. maintained by continental stock transfer & trust company, acting as trustee. an audited balance sheet as of july 21, 2020 reflecting receipt of the proceeds upon consummation of the ipo and the private placement has been issued by the company and is included as exhibit 99.1 to this current report on form 8-k. item 9.01financial statements and exhibits. (d) exhibits exhibit index exhibit no. description 99.1 audited balance sheet as of july 21, 2020. signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. deerfield healthcare technology acquisitions corp. by: /s/ christopher wolfe name: christopher wolfe title: chief financial officer dated: july 27, 2020 ",https://www.sec.gov/Archives/edgar/data/1813914/000110465920086814/0001104659-20-086814-index.htm,8-K,2020-07-27 16:01:17
2020-07-21," 8-k 1 tm2021466-10_8k.htm form 8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): july 21, 2020 (july 16, 2020) deerfield healthcare technology acquisitions corp. (exact name of registrant as specified in its charter) delaware (state or other jurisdiction of incorporation) 001-39391 (commission file number) 85-0992224 (irs employer identification no.) 780 third avenue, 37th floor new york, new york 10017 (address of principal executive offices, including zip code) registrant’s telephone number, including area code: (212) 551-1600 not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ¨soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ¨pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ¨pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (§230.405 of this chapter) or rule 12b-2 of the securities exchange act of 1934 (§240.12b-2 of this chapter). emerging growth company x if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one share of class a common stock and one-fifth of one redeemable warrant dfhtu the nasdaq stock market llc class a common stock, par value $0.0001 per share dfht the nasdaq stock market llc warrants, each whole warrant exercisable for one share of class a common stock, each at an exercise price of $11.50 per share dfhtw the nasdaq stock market llc item 1.01.entry into a material definitive agreement. on july 21, 2020, deerfield healthcare technology acquisitions corp. (the “company”) consummated its initial public offering (“ipo”) of 14,375,000 (the “units”), including the issuance of 1,875,000 units as a result of the underwriters’ exercise of their over-allotment option in full. each unit consists of one share of class a common stock of the company, par value $0.0001 per share, and one-fifth of one redeemable warrant of the company (“warrant”), with each whole warrant entitling the holder thereof to purchase one share of class a common stock for $11.50 per share, subject to adjustment. the units were sold at a price of $10.00 per unit, generating gross proceeds to the company of $143,750,000. in connection with the ipo, the company entered into the following agreements, forms of which were previously filed as exhibits to the company’s registration statement on form s-1 (file no. 333-239580) for the ipo, initially filed with the u.s. securities and exchange commission (the “commission”) on june 30, 2020, as amended (the “registration statement”): ·an underwriting agreement, dated july 16, 2020, by and among the company and deutsche bank securities inc. and ubs securities llc, as representatives of the several underwriters, a copy of which is attached as exhibit 1.1 hereto and incorporated herein by reference. ·a warrant agreement, dated july 16, 2020, by and between the company and continental stock transfer & trust company, as warrant agent, a copy of which is attached as exhibit 4.1 hereto and incorporated herein by reference. ·a letter agreement, dated july 16, 2020 (the “letter agreement”), by and among the company, its executive officers, its directors and dfhta sponsor llc, a copy of which is attached as exhibit 10.1 hereto and incorporated herein by reference. ·an investment management trust agreement, dated july 16, 2020, by and between the company and continental stock transfer & trust company, as trustee, a copy of which is attached as exhibit 10.3 hereto and incorporated herein by reference. ·a registration rights agreement, dated july 16, 2020, by and among the company, dfhta sponsor llc and the other holders party thereto, a copy of which is attached as exhibit 10.4 hereto and incorporated herein by reference. ·a private placement warrants purchase agreement, dated july 16, 2020, by and among the company and dfhta sponsor llc (the “private placement warrants purchase agreement”), a copy of which is attached as exhibit 10.5 hereto and incorporated herein by reference. ·an administrative services agreement, dated july 16, 2020, by and between the company and dfhta sponsor llc, a copy of which is attached as exhibit 10.6 hereto and incorporated herein by reference. ·a strategic services agreement, dated july 16, 2020, by and between the company and christopher wolfe, a copy of which is attached as exhibit 10.7 hereto and incorporated herein by reference. on july 16, 2020, the company also entered into a letter agreement (the “deerfield letter agreement”) with deerfield partners, l.p. (“deerfield”) pursuant to which the company has agreed to not complete a business combination without the consent of deerfield, which consent deerfield has indicated it does not intend to provide if the company's proposed initial business combination is with a target that is not primarily engaged in the healthcare industry. the foregoing description of the deerfield letter agreement does not purport to be complete and is qualified in its entirety by reference to the deerfield letter agreement, a copy of which is filed as exhibit 10.2 hereto and incorporated herein by reference. item 3.02.unregistered sales of equity securities. simultaneously with the closing of the ipo, pursuant to the private placement warrants purchase agreement, the company completed the private sale of an aggregate of 2,916,667 warrants (the “private placement warrants”) to dfhta sponsor llc at a purchase price of $1.50 per private placement warrant, generating gross proceeds to the company of $4,375,000. the private placement warrants are identical to the warrants sold in the ipo, except that the private placement warrants, so long as they are held by dfhta sponsor llc or its permitted transferees, (i) are not redeemable by the company, (ii) may not (including the class a common stock issuable upon exercise of such private placement warrants), subject to certain limited exceptions, be transferred, assigned or sold by such holders until 30 days after the completion of the company’s initial business combination, (iii) may be exercised by the holders on a cashless basis and (iv) will be entitled to registration rights. no underwriting discounts or commissions were paid with respect to such sale. the issuance of the private placement warrants was made pursuant to the exemption from registration contained in section 4(a)(2) of the securities act of 1933, as amended. item 5.02.departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers. on july 16, 2020, in connection with the ipo, dr. peter j. fitzgerald, dr. linda grais and hon. dr. david j. shulkin (the “directors”) were appointed to the board of directors of the company (the “board”). the directors are independent directors. effective july 16, 2020, the directors were appointed to the board’s audit committee, with dr. grais serving as chair of the audit committee. effective july 16, 2020, drs. fitzgerald, grais and shulkin were also appointed to the board’s compensation committee, with dr. shulkin serving as chair of the compensation committee. following the appointment of the directors, the board is comprised of the following three classes: the term of office of the first class of directors, class i, consists of drs. grais and shulkin and will expire at the company’s first annual meeting of stockholders; the term of office of the second class of directors, class ii, consists of richard barasch and steven hochberg and will expire at the company’s second annual meeting of stockholders; and the term of office of the third class of directors, class iii, consists of dr. fitzgerald and will expire at the company’s third annual meeting of stockholders. on july 16, 2020, in connection with their appointments to the board, each director entered into the letter agreement as well as an indemnity agreement with the company in the form previously filed as exhibit 10.5 to the registration statement. in addition, in june 2020, dfhta sponsor llc, the company’s sponsor, transferred 25,000 shares of class b common stock of the company to each of the directors for the same per-share price initially paid by dfhta sponsor llc. other than the foregoing, none of the directors are party to any arrangement or understanding with any person pursuant to which they were appointed as directors, nor are they party to any transactions required to be disclosed under item 404(a) of regulation s-k involving the company. the foregoing descriptions of the letter agreement and the form of indemnity agreement do not purport to be complete and are qualified in their entireties by reference to the letter agreement and form of indemnity agreement, copies of which are attached as exhibit 10.1 hereto and exhibit 10.5 to the registration statement, respectively, and are incorporated herein by reference. item 5.03.amendments to certificate of incorporation or bylaws. on july 16, 2020, in connection with the ipo, the company adopted its second amended and restated certificate of incorporation (the “amended charter”), effective the same day. the terms of the amended charter are set forth in the registration statement and are incorporated herein by reference. a copy of the amended charter is attached as exhibit 3.1 hereto and incorporated herein by reference. item 8.01.other events. a total of $143,750,000, comprised of $141,211,000 of the proceeds from the ipo (which amount includes $4,443,250 of the underwriters’ deferred discount) and $2,539,000 of the proceeds of the sale of the private placement warrants, was placed in a u.s.-based trust account at j.p. morgan chase bank, n.a. maintained by continental stock transfer & trust company, acting as trustee. except with respect to interest earned on the funds held in the trust account that may be released to the company to pay its taxes, the funds held in the trust account will not be released from the trust account until the earliest of (i) the completion of the company’s initial business combination, (ii) the redemption of any shares of class a common stock included in the units sold in the ipo (“public shares”) properly submitted in connection with a stockholder vote to amend the company’s amended charter to modify the substance or timing of the company’s obligation to redeem 100% of the public shares if the company does not complete its initial business combination within 24 months from the closing of the ipo or with respect to any other material provisions relating to stockholders’ rights or pre-initial business combination activity and (iii) the redemption of the public shares if the company is unable to complete an initial business combination within 24 months from the closing of the ipo, subject to applicable law. on july 16, 2020, the company issued a press release announcing the pricing of the ipo, a copy of which is attached as exhibit 99.1 to this current report on form 8-k. on july 21, 2020, the company issued a press release announcing the closing of the ipo, a copy of which is attached as exhibit 99.2 to this current report on form 8-k. item 9.01.financial statements and exhibits. (d)exhibits exhibit index exhibit no. description 1.1 underwriting agreement, dated july 16, 2020, by and among the company and deutsche bank securities inc. and ubs securities llc, as representatives of the several underwriters. 3.1 second amended and restated certificate of incorporation. 4.1 warrant agreement, dated july 16, 2020, by and between the company and continental stock transfer & trust company, as warrant agent. 10.1 letter agreement, dated july 16, 2020, by and among the company, its executive officers, its directors and dfhta sponsor llc. 10.2 letter agreement, dated july 16, 2020, by and between the company and deerfield partners, l.p. 10.3 investment management trust agreement, dated july 16, 2020, by and between the company and continental stock transfer & trust company, as trustee. 10.4 registration rights agreement, dated july 16, 2020, by and among the company, dfhta sponsor llc and the other holders party thereto. 10.5 private placement warrants purchase agreement, dated july 16, 2020, by and among the company and dfhta sponsor llc. 10.6 administrative services agreement, dated july 16, 2020, by and between the company and dfhta sponsor llc. 10.7 strategic services agreement, dated july 16, 2020, by and between the company and christopher wolfe. 99.1 press release, dated july 16, 2020. 99.2 press release, dated july 21, 2020. signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. deerfield healthcare technology acquisitions corp. by: /s/ christopher wolfe name: christopher wolfe title: chief financial officer dated: july 21, 2020 ",https://www.sec.gov/Archives/edgar/data/1813914/000110465920085277/0001104659-20-085277-index.htm,8-K,2020-07-21 16:17:08
